



## **Eidos Therapeutics to Present at the Leerink Partners Roundtable Series: Rare Disease & Oncology**

September 25, 2018

SAN FRANCISCO, Sept. 25, 2018 (GLOBE NEWSWIRE) -- [Eidos Therapeutics](#), Inc. (Eidos) (Nasdaq:[EIDX](#)) today announced that management will participate in a fireside chat at the Leerink Partners Roundtable Series: Rare Disease & Oncology on Tuesday, October 2, 2018 at 3:30 p.m. ET. The conference will be held in New York, NY.

A live audio webcast of the presentation can be accessed through the Events & Presentations section of the company's website at [ir.eidostx.com](http://ir.eidostx.com). An archived replay of the webcast will be available on the company's website for 90 days following the live presentation.

### **About Eidos Therapeutics**

Eidos Therapeutics is a clinical stage biopharmaceutical company focused on addressing the large and growing unmet need in diseases caused by transthyretin, or TTR, amyloidosis, or ATTR. We seek to treat this well-defined family of diseases at their collective source by stabilizing TTR. Our product candidate, AG10, an orally-administered small molecule designed to potently stabilize TTR, is a potentially best-in-class treatment aiming to halt the progression of ATTR diseases.

Founded in 2013, Eidos is led by a team of industry veterans who are responsible for developing over 30 molecules through IND applications and more than 10 approved drugs. Together with patients and physicians, we aim to bring a safe, effective and disease-modifying treatment for ATTR to market as quickly as possible.

### **Media Contact:**

Carolyn Hawley, Canale Communications, (619) 849-5382, [carolyn@canalecomm.com](mailto:carolyn@canalecomm.com)

### **For Investors**

Alex Gray, Burns McClellan, (212) 213-0006, [agrav@burnsmc.com](mailto:agrav@burnsmc.com)



Source: Eidos Therapeutics, Inc.